Research and Markets: Tanox's Therapeutic Emphasis is on the Areas of Immunology (Asthma/Allergy and Autoimmune Diseases), Infectious Diseases, and Oncology
Posted on: Monday, 3 December 2007, 12:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c76193) has announced the addition of Premium Company Profile - Tanox to their offering.
Introduction
Tanox identifies and develops therapeutic monoclonal antibodies to address significant unmet medical needs in the areas of immunology, infectious diseases and cancer. In January 2007, the stockholders of Tanox approved the merger with Genentech for $20 per share for a total cash value of approximately $919 million.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Tanox is a biopharmaceutical company focused on discovering and developing therapeutic monoclonal antibodies that influence or are derived from the immune system. The company's therapeutic emphasis is on the areas of immunology (asthma/allergy and autoimmune diseases), infectious diseases, and oncology. Tanox derives its revenues from royalties, license fees, development and manufacturing right, and profit sharing for its humanized monoclonal antibody product, Xolair.
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company's adjusted five year financial data along with key ratios and market capitalization
Content Outline:
Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products & Services
Marketed Products
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Top Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Manufacturing
Scorecard
Overview
Scorecard Analysis
Financial and Operational Overview
Appendix
Ask the analyst
Disclaimer
Table of Figures
Table of Tables
For more information visit http://www.researchandmarkets.com/reports/c76193
Source: Datamonitor
Source: Business Wire
Related Articles
- Optimum Lightpath Names John Macario as Senior Vice President of Product Strategy and Management
- Jack Mahoney, MD, Chief Medical Officer, Center for Health Value Innovation, Articulates Value-Based Strategies for Rx Benefit Management
- Research and Markets: New Report Reveals Key Analysis of Tomkins Plc and Their Competitors
- Resolution Health Taps Health Care Economist Susheel Jain As VP, Corporate and Product Strategy
- S3 Announces the Appointment of George Mudie As Director of Product Strategy, Consumer Systems
- Sargold Targets Longer Term Production Strategy at Furtei
- Few Multinationals Have Implemented a Health and Productivity Strategy Outside the United States
- View This Comprehensive Strategic Analysis of the Latest Trends in the World Market for OTC Healthcare With an Overview of 14 Product Sectors
- Reimbursement Regulations Underline the Need for Innovative Marketing and Product Strategies in the European Enteral Feeds Market
- Resolution Health Inc. (RHI) Expands Management Team; Healthcare Veteran Alan Wright, MD, MPH, Named Vice President of Product Strategy and Business Development
 |
 |
User Comments (0)
RSS Feeds